When the Trump administration accused China of “unfairly” using venture capital to acquire technologies last month, it singled out the firm 6 Dimensions Capital, calling it a suspicious agent of the Chinese government bent on acquiring U.S. biotechnology.
That came as a surprise to 6 Dimensions’ CEO, Leon Chen, who said neither he nor anyone at his firm had ever been contacted by the U.S. trade representative, which issued the report naming his firm.
About the Author Reprints
good news
Want to read